Pediatric ObesityNCT03139877
Pediatric Obesity Observational Prospective Trial
An observational study of Pediatric Obesity, run by Duke University at 1 site in United States.
Trial summary
Using an observational case-control cohort design, the investigator aims to define the mechanisms underlying microbiome regulation of metabolism in adolescence before and after medically indicated therapies for obesity. Read more about this study
- Who is it for?
- Ages 10 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Pediatric Obesity
- How many people
- 295 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Sep 2016to 7 Jan 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Duke Healthy Lifestyles (HL) Clinic Patients with BMI>95% 1. c) Normal-weight siblings of patients presenting to the Duke Healthy Lifestyles Clinic 2. c) Normal weight age/sex-matched controls presenting for well-child care to Duke Children's Primary Care clinic
Who may be able to join
- Child aged 10-18 years
- Sexual Maturity Rating 2 or above (pubertal)
- Age- and gender-specific BMI ≥ 95th percentile
- Expected enrollment in Healthy Lifestyles Clinical Program > 6 months
Who cannot join
- Antibiotic use in the 1 month prior to expected enrollment
- Anticipated antibiotic use during the course of the study.
- Immunodeficiency or prior transplantation
- Type 1 diabetes mellitus
- Inborn error of metabolism
- No fluency in English or Spanish
Show all 13Show fewer
- Identifiable cause of obesity including hypothyroidism, Cushing syndrome, known genetic obesity syndrome including melanocortin receptor 4 mutation, drug-induced obesity including steroids or anti-psychotics
- Significant medical or mental health condition that precludes treatment
- Receiving insulin
- Plans to move away from area in next 6 months
- Weight loss of >5% total body weight in prior 3 months
- Pregnancy (self-report, confirm with noted last menstrual period in chart)
- Home outside of a 50 mile radius from the HL Clinic.
Trial locations and contacts
1 site in 1 country.
United States1 site
Duke University Health System
Durham, North Carolina, 27710
About this study
Official title: Pediatric Obesity Observational Prospective Trial: Microbiome and Metabolism During Obesity Target Therapeutics
Using an observational case-control cohort design, the investigator aims to define the mechanisms underlying microbiome regulation of metabolism in adolescence before and after medically indicated therapies for obesity. The investigator's overarching hypothesis is that gut bacteria control host weight, insulin sensitivity, and response to weight-loss treatments by modifying host metabolism.
Read the detailed description
Intervention Cohorts: A prospective, longitudinal observational case control study will be performed. All subjects will receive Healthy Lifestyle Program (HLP) standard of care, which includes intensive lifestyle modification and free participation in Bull City Fit. Four groups of participants receiving obesity treatment will be enrolled: (1) HLP-only, (2) HLP + Low carbohydrate diet, (3) HLP + weight loss medication(s) and (4) HLP + Bariatric surgery. Consistent with the observational design of this study, study participants will be assigned to each group as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference.
Comparison Cohort: two comparison groups be enrolled:(1c) healthy siblings of enrolled intervention subjects and (2c) age/sex matched controls recruited from the Duke Children's Primary Care Clinic.
Up to 350 participants will be enrolled, with the goal of 295 evaluable participant data. The study period is six months for all groups with the exception of the bariatric surgery group which will last from baseline until after surgery, up to 12 months. The comparison groups will have one visit at baseline only.
Stool Sample Collection: Participants in both intervention and comparison groups will provide a fecal sample at enrollment or within 3 days of enrollment. Participants in intervention groups (Groups 1-4) will provide additional fecal samples at 1.5, 3, 4.5, and 6 months. Given that the ability to collect fecal samples is unpredictable, the investigator will develop a standard operating procedure along the following guidelines:
- At the first visit, if the subject cannot provide a sample at the time of enrollment, the investigator will give the participant/parent a cooler/ice pack and sample collection kit. The investigator will ask the subject to provide the "baseline" sample within 3 days of the first visit. The sample will be refrigerated for up to 24 hours prior to pick up by the clinical research staff or delivery by the parent/guardian, with compensation for miles. With pick up or delivery a new cooler and freezer pack as well as sample collection kit will be provided for the following sample collection.
- Within a 2-week window, centered on collection points 1.5 and 4.5 months, the subjects will provide additional samples. They may either have the samples picked up within 24 hours of collection (with refrigeration from collection to pick up) or get reimbursed for mileage.
- For the 3-month and 6-month collections, which occur in conjunction with a regularly scheduled Healthy Lifestyles visit, the patients will collect a sample within 24 hours prior to the visit and bring with them to clinic. At the 3-month visit they will be sent home with new collection kits, freezer packs, and coolers.
- If a patient cannot provide a sample within 24 hours of a clinic visit or a sample is missed, we will still collect a sample as soon as the patient is able to provide it and arrange for pickup or delivery as outlined below, noting the sample as "out of window."
Plasma sample collection: Participants in intervention groups will provide a 20mL blood samples at baseline, 3 and 6 months at the time of a regular HLP visit. The standard HLP clinical protocol is to draw fasting labs at baseline and 6 months, so no additional blood draws beyond what is required for clinical care will be required at those visits. However, HLP patients do not typically have a blood draw at 3 months, so participants will be asked for a blood sample at 3 months they would not otherwise require. Participants in comparison groups (Groups 1c, 2c) will be asked for a blood sample at enrollment only; they would not otherwise require this sample.
Analysis of samples: Fecal samples will be analyzed for the composition of the microbiota using DNA sequencing methods. Specific bacteria associated with obesity will be isolated from fecal samples and studied in the laboratory for their metabolism. A subset of fecal samples will be transferred into the intestinal tracts of germ free mice to study the effects on their metabolism. Participant plasma will be analyzed for panels of metabolites that are associated with diabetes mellitus and obesity. Blood mononuclear cell DNA will be used for focused genetic testing to identify genetic changes associated with obesity.
- Conditions
- Pediatric Obesity
- Medical subject headings
- Pediatric Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| HLP | Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile. Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery. Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference. | |
| Healthy Weight Siblings | Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point. | |
| Healthy Weight age/sex matched controls | Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Body Mass Index (kg/m2)
We will measure weight (in kilograms) and height (in cm) for all subjects at baseline and at 6 months (12 months for the surgery group). The between-group difference in Body Mass Index change will be reported.
Measured: Baseline and 6 months
Secondary outcomes (6)
Change in blood pressure
Blood pressure will be measured at baseline and 6-months (12-months for the surgery group) using standard methods, and change in blood pressure between groups will be reported
Measured: Baseline and 6 months
Change in cardiovascular fitness
We will perform a 3-minute standardized stepping test at baseline and 6-months (12 months for surgery group) and compare between-group differences in heart rate change with step test.
Measured: Baseline and 6 months
Change in fasting blood cholesterol
We will measure fasting blood cholesterol at baseline and at 6-months (12 months for surgery group) and compare between-group differences in total cholesterol.
Measured: Baseline and 6 months
Change in fasting blood glucose
We will measure fasting blood glucose at baseline and at 6-months (12 months for surgery group) and compare between-group differences in fasting blood glucose.
Measured: Baseline and 6 months
Change in stool microbiota profile
Fecal samples will be analyzed for the composition of the microbiota by extracting and sequencing the RNA from the organisms. We will report the communities of microbes at each time point.
Measured: Baseline and every 6 weeks up to 6 months (0m, 1.5m, 3m, 4.5m, 6m)
Change in blood metabolites
Blood samples will be analyzed for a panel of metabolites that may be produced by the intestinal microbiota. We will report the metabolic profiles at each time point.
Measured: Baseline, 3 months and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2017
- Study start13 Sep 2016
- Primary completion7 Jan 2020
- Study completion7 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Pediatric ObesityStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 295 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sarah C Armstrong, MD, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03139877
- Sponsor's protocol ID
- Pro00074729
- Status last verified
- Jun 2021
- First submitted
- 15 Mar 2017
- Last updated
- 18 Jun 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
McCann JR, Yang C, Bihlmeyer NA, Tang R, Truong T, Zhou W, An J, Jawahar J, Ilkayeva O, Muehlbauer MJ, Hu Z, Dressman HK, Poppe L, Granek JA, Arnold JW, David LA, Oh J, Shi P, Gumus Balikcioglu P, Shah SH, Armstrong SC, Newgard CB, Seed PC, Rawls JF. Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy. J Clin Invest. 2026 Jul 15;136(14):e196742. doi: 10.1172/JCI196742. eCollection 2026 Jul 15.
PubMed 42454489McCann JR, Yang C, Bihlmeyer NA, Tang R, Truong T, An J, Jawahar J, Ilkayeva O, Muehlbauer MJ, Hu Z, Dressman HK, Poppe L, Granek JA, David LA, Shi P, Balikcioglu PG, Shah SH, Armstrong SC, Newgard CB, Seed PC, Rawls JF. Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy. medRxiv [Preprint]. 2025 Jun 9:2025.02.03.25321363. doi: 10.1101/2025.02.03.25321363.
PubMed 39974080Suarez L, Skinner AC, Truong T, McCann JR, Rawls JF, Seed PC, Armstrong SC. Advanced Obesity Treatment Selection among Adolescents in a Pediatric Weight Management Program. Child Obes. 2022 Jun;18(4):237-245. doi: 10.1089/chi.2021.0190. Epub 2021 Nov 9.
PubMed 34757829
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pediatric Obesity Observational Prospective Trial: Microbiome and Metabolism During Obesity Target Therapeutics
- ClinicalTrials.gov ID
- NCT03139877
- Acronym / sponsor ID
- Pro00074729
- Conditions
- Pediatric Obesity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 295 participants (actual)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Study start
- 13 Sep 2016 (actual)
- Primary completion
- 7 Jan 2020 (actual)
- Study completion
- 7 Jan 2020 (actual)
- First posted
- 4 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Using an observational case-control cohort design, the investigator aims to define the mechanisms underlying microbiome regulation of metabolism in adolescence before and after medically indicated therapies for obesity. The investigator's overarching hypothesis is that gut bacteria control host weight, insulin sensitivity, and response to weight-loss treatments by modifying host metabolism.
Detailed description
Intervention Cohorts: A prospective, longitudinal observational case control study will be performed. All subjects will receive Healthy Lifestyle Program (HLP) standard of care, which includes intensive lifestyle modification and free participation in Bull City Fit. Four groups of participants receiving obesity treatment will be enrolled: (1) HLP-only, (2) HLP + Low carbohydrate diet, (3) HLP + weight loss medication(s) and (4) HLP + Bariatric surgery. Consistent with the observational design of this study, study participants will be assigned to each group as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference.
Comparison Cohort: two comparison groups be enrolled:(1c) healthy siblings of enrolled intervention subjects and (2c) age/sex matched controls recruited from the Duke Children's Primary Care Clinic.
Up to 350 participants will be enrolled, with the goal of 295 evaluable participant data. The study period is six months for all groups with the exception of the bariatric surgery group which will last from baseline until after surgery, up to 12 months. The comparison groups will have one visit at baseline only.
Stool Sample Collection: Participants in both intervention and comparison groups will provide a fecal sample at enrollment or within 3 days of enrollment. Participants in intervention groups (Groups 1-4) will provide additional fecal samples at 1.5, 3, 4.5, and 6 months. Given that the ability to collect fecal samples is unpredictable, the investigator will develop a standard operating procedure along the following guidelines:
- At the first visit, if the subject cannot provide a sample at the time of enrollment, the investigator will give the participant/parent a cooler/ice pack and sample collection kit. The investigator will ask the subject to provide the "baseline" sample within 3 days of the first visit. The sample will be refrigerated for up to 24 hours prior to pick up by the clinical research staff or delivery by the parent/guardian, with compensation for miles. With pick up or delivery a new cooler and freezer pack as well as sample collection kit will be provided for the following sample collection.
- Within a 2-week window, centered on collection points 1.5 and 4.5 months, the subjects will provide additional samples. They may either have the samples picked up within 24 hours of collection (with refrigeration from collection to pick up) or get reimbursed for mileage.
- For the 3-month and 6-month collections, which occur in conjunction with a regularly scheduled Healthy Lifestyles visit, the patients will collect a sample within 24 hours prior to the visit and bring with them to clinic. At the 3-month visit they will be sent home with new collection kits, freezer packs, and coolers.
- If a patient cannot provide a sample within 24 hours of a clinic visit or a sample is missed, we will still collect a sample as soon as the patient is able to provide it and arrange for pickup or delivery as outlined below, noting the sample as "out of window."
Plasma sample collection: Participants in intervention groups will provide a 20mL blood samples at baseline, 3 and 6 months at the time of a regular HLP visit. The standard HLP clinical protocol is to draw fasting labs at baseline and 6 months, so no additional blood draws beyond what is required for clinical care will be required at those visits. However, HLP patients do not typically have a blood draw at 3 months, so participants will be asked for a blood sample at 3 months they would not otherwise require. Participants in comparison groups (Groups 1c, 2c) will be asked for a blood sample at enrollment only; they would not otherwise require this sample.
Analysis of samples: Fecal samples will be analyzed for the composition of the microbiota using DNA sequencing methods. Specific bacteria associated with obesity will be isolated from fecal samples and studied in the laboratory for their metabolism. A subset of fecal samples will be transferred into the intestinal tracts of germ free mice to study the effects on their metabolism. Participant plasma will be analyzed for panels of metabolites that are associated with diabetes mellitus and obesity. Blood mononuclear cell DNA will be used for focused genetic testing to identify genetic changes associated with obesity.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| HLP | – | –Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile. Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery. Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference. |
| Healthy Weight Siblings | – | –Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point. |
| Healthy Weight age/sex matched controls | – | –Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point. |
Who may qualify
- Ages
- 10 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Duke Healthy Lifestyles (HL) Clinic Patients with BMI>95% 1. c) Normal-weight siblings of patients presenting to the Duke Healthy Lifestyles Clinic 2. c) Normal weight age/sex-matched controls presenting for well-child care to Duke Children's Primary Care clinic
Key inclusion criteria (4 listed)
- Child aged 10-18 years
- Sexual Maturity Rating 2 or above (pubertal)
- Age- and gender-specific BMI ≥ 95th percentile
- Expected enrollment in Healthy Lifestyles Clinical Program > 6 months
Key exclusion criteria (13 listed)
- Antibiotic use in the 1 month prior to expected enrollment
- Anticipated antibiotic use during the course of the study.
- Immunodeficiency or prior transplantation
- Type 1 diabetes mellitus
- Inborn error of metabolism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in Body Mass Index (kg/m2)
Time frame: Baseline and 6 months
We will measure weight (in kilograms) and height (in cm) for all subjects at baseline and at 6 months (12 months for the surgery group). The between-group difference in Body Mass Index change will be reported.
6 secondary outcomes
Change in blood pressure
Time frame: Baseline and 6 months
Change in cardiovascular fitness
Time frame: Baseline and 6 months
Change in fasting blood cholesterol
Time frame: Baseline and 6 months
Change in fasting blood glucose
Time frame: Baseline and 6 months
Change in stool microbiota profile
Time frame: Baseline and every 6 weeks up to 6 months (0m, 1.5m, 3m, 4.5m, 6m)
Change in blood metabolites
Time frame: Baseline, 3 months and 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2021.
- Derived from this study: PubMed 42454489McCann JR, Yang C, Bihlmeyer NA, Tang R, Truong T, Zhou W, An J, Jawahar J, Ilkayeva O, Muehlbauer MJ, Hu Z, Dressman HK, Poppe L, Granek JA, Arnold JW, David LA, Oh J, Shi P, Gumus Balikcioglu P, Shah SH, Armstrong SC, Newgard CB, Seed PC, Rawls JF. Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy. J Clin Invest. 2026 Jul 15;136(14):e196742. doi: 10.1172/JCI196742. eCollection 2026 Jul 15.
- Derived from this study: PubMed 39974080McCann JR, Yang C, Bihlmeyer NA, Tang R, Truong T, An J, Jawahar J, Ilkayeva O, Muehlbauer MJ, Hu Z, Dressman HK, Poppe L, Granek JA, David LA, Shi P, Balikcioglu PG, Shah SH, Armstrong SC, Newgard CB, Seed PC, Rawls JF. Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy. medRxiv [Preprint]. 2025 Jun 9:2025.02.03.25321363. doi: 10.1101/2025.02.03.25321363.
- Derived from this study: PubMed 34757829Suarez L, Skinner AC, Truong T, McCann JR, Rawls JF, Seed PC, Armstrong SC. Advanced Obesity Treatment Selection among Adolescents in a Pediatric Weight Management Program. Child Obes. 2022 Jun;18(4):237-245. doi: 10.1089/chi.2021.0190. Epub 2021 Nov 9.
- Individual participant dataSharing planned: No
Related trials for Pediatric Obesity
Enrolling by invitation
Impact of a Playful Family Education Strategy With ICT on Childhood Obesity Prevention
Pediatric Obesity, Childhood Obesity
Not yet recruiting
Effectiveness of a 10-week Multicomponent Intervention Combined With Parent Education on Binge Eating Behavior in Children and Adolescents
Binge Eating Disorder, Binge Eating
Active, not recruiting
Growing Healthy Children and Families in Rural Arkansas
Pediatric Obesity, Health Behavior, Risky
Recruiting
Cities for Better Health Childhood Obesity Prevention Initiative in JAPAN
Quality of Life (QOL), Nutrition
RecruitingPhase 3
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
Obesity, Childhood, Insulin Resistance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah C Armstrong, MD principal investigator
Duke University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pediatric Obesity, run by Duke University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Body Mass Index (kg/m2) (time frame: Baseline and 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03139877, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2021; AzTrials last refreshed its copy on 31 Oct 2026.